1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Harbour BioMed Acquires Harbour Antibodies BV

M&A Deal Summary

Harbour BioMed Acquires Harbour Antibodies BV

On December 19, 2016, Harbour BioMed acquired life science company Harbour Antibodies BV

Acquisition Highlights
  • This is Harbour BioMed’s 1st transaction in the Life Science sector.
  • This is Harbour BioMed’s 1st transaction in the United States.
  • This is Harbour BioMed’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2016-12-19
Target Harbour Antibodies BV
Sector Life Science
Buyer(s) Harbour BioMed
Deal Type Add-on Acquisition

Target

Harbour Antibodies BV

Cambridge, Massachusetts, United States
Harbour Antibodies BV is a developer of two types of human immunoglobulin gene transgenic mice: mice that generate “conventional” tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs).

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Harbour BioMed

Shanghai, China
Category Company
Sector Life Science
DESCRIPTION

Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer with a focus on immuno-oncology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2016 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal